Apotex Inc. / Cumberland Pharmaceuticals branded U.S. commercial business

Hospital and specialty pharmaceutical indications (osmotic constipation, IV pain, chemotherapy-induced nausea, hospital-acquired pneumonia, acetaminophen overdose, hyponatremia, H. pylori)

$44M US Market · $44.5M Cumberland 2025 annual revenue (proxy for portfolio scale)

Disease Overview

Cumberland's branded portfolio addresses a heterogeneous mix of acute care and specialty indications. Kristalose (lactulose) treats chronic and acute constipation, including hepatic encephalopathy management. Caldolor (IV ibuprofen) is the first FDA-approved IV NSAID for pain and fever. Sancuso (granisetron transdermal patch) prevents chemotherapy-induced nausea and vomiting (CINV) for moderately/highly emetogenic regimens. Vibativ (telavancin) treats hospital-acquired/ventilator-associated bacterial pneumonia caused by S. aureus including MRSA. Acetadote (IV acetylcysteine) is the standard antidote for acetaminophen overdose, the leading cause of acute liver failure in the US (~50,000 ER visits annually per CDC). Vaprisol (conivaptan) treats euvolemic and hypervolemic hyponatremia in hospitalized patients. Talicia is a fixed-dose triple-combination (omeprazole + amoxicillin + rifabutin) for H. pylori eradication, an infection affecting roughly 35% of US adults. Combined, these are mature niche assets with stable hospital and specialty demand but limited growth.

Competitive Landscape

Each Cumberland asset competes in a distinct niche. Caldolor competes with Pacira's Exparel and other IV/oral NSAIDs in post-surgical pain. Sancuso transdermal granisetron competes with oral/IV ondansetron generics and palonosetron (Aloxi). Vibativ telavancin competes with vancomycin generics, linezolid, daptomycin, and ceftaroline in MRSA hospital-acquired pneumonia, where formulary preference favors lower-cost agents. Acetadote IV acetylcysteine has limited branded competition (most acetaminophen-overdose protocols use oral or generic IV NAC). Vaprisol competes with tolvaptan (Samsca/Jynarque, Otsuka) and fluid restriction protocols. Talicia competes with legacy clarithromycin-based H. pylori triple therapy and Pylera (bismuth quadruple). Apotex, the largest Canadian-based pharmaceutical company, is using this asset purchase to expand its US specialty/hospital footprint beyond its dominant generics base. Five to ten years post-close, Apotex's path is preservation and modest cash extraction, not growth: success means stable hospital channel revenue funding broader US specialty platform build-out, while Cumberland (CPIX) becomes a pure-play ifetroban biotech with binary readouts in DMD cardiomyopathy and systemic sclerosis.